无创胎儿游离DNA血型检测在产前诊断中的研究进展*

doi:10.3969/j.issn.1671-2587.2024.06.020

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (6): 835-842.DOI: 10.3969/j.issn.1671-2587.2024.06.020

无创胎儿游离DNA血型检测在产前诊断中的研究进展^*

任道菊¹, 李小薇², 李翠莹^1,2

¹安徽医科大学第五临床医学院空军临床学院;
²空军军医大学空军特色医学中心输血科,北京 100142

收稿日期:2024-06-18 出版日期:2024-12-20 发布日期:2024-12-20
通讯作者: 李翠莹,主要从事临床输血及免疫血液学研究,（E-mail）licuiying2013@qq.com。
作者简介:任道菊,主要从事临床输血及免疫血液学研究,（E-mail）rendaoju1@163.com。
基金资助:
*本课题受空军特色医学中心青年人才项目（No.2022YXQN028）资助

Advances in Non-invasive Cell-free Fetal DNA Blood Group Testing in Prenatal Diagnosis

REN Daoju¹, LI Xiaowei², LI Cuiying^1,2

¹Air Force Clinical College; the Fifth School of Clinical Medicine, Anhui Medical University, Hefei,232001;
²Department of Blood Transfusion, Air Force Medical Center, Air Force Medical University, Beijing, 100142

Received:2024-06-18 Online:2024-12-20 Published:2024-12-20

摘要/Abstract

摘要： 胎儿游离DNA（cell-free fetal DNA, cff-DNA）存在于孕妇妊娠期外周血中,其为携带胎儿相关遗传信息的DNA片段,可以进行胎儿染色体、基因相关疾病筛查。因其操作风险低、无副作用,目前已被广泛用于无创产前诊断检测（non-invasive prenatal testing, NIPT）。无创cff-DNA血型检测是运用分子生物学检测cff-DNA血型相关基因,得出胎儿血型结果。以此在妊娠期即可检测出胎母血型是否一致,判断胎儿有无发生血型不合所致胎儿新生儿溶血病（hemolytic disease of the fetus and newborn, HDFN）的风险。

关键词: 胎儿游离DNA, 胎儿血型, 无创产前检测

Abstract: Cell-free fetal DNA (cff-DNA) exists in the peripheral blood of pregnant women during gestation, and it carries DNA fragments with relevant genetic information of the fetus, which can be screened for fetal chromosomal and gene-related diseases. It is now widely used in non-invasive prenatal testing (NIPT) because of its low operational risk and lack of side effects. Non-invasive cff-DNA blood group testing uses molecular technology to detect the genes associated with cff-DNA blood grouping, resulting in a fetal blood group. The test can be used to detect the consistency of fetal and maternal blood groups during pregnancy and to determine the risk of hemolytic disease of the fetus and newborn (HDFN) due to blood group incompatibility.

Key words: Cell free fetal DNA, Fetal blood type, Non-invasive prenatal testing

中图分类号:

R457

任道菊, 李小薇, 李翠莹. 无创胎儿游离DNA血型检测在产前诊断中的研究进展^*[J]. 临床输血与检验, 2024, 26(6): 835-842.

REN Daoju, LI Xiaowei, LI Cuiying. Advances in Non-invasive Cell-free Fetal DNA Blood Group Testing in Prenatal Diagnosis[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 835-842.

参考文献

[1] CHITTY L S,KHALIL A,BARRETT A N,et al.Safe,accurate,prenatal diagnosis of thanatophoric dysplasia using ultrasound and free fetal DNA[J]. Prenat Diagn,2013,33(5):416-423.
[2] CHITTY L S,MASON S,BARRETT A N,et al.Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia:next-generation sequencing allows for a safer,more accurate,and comprehensive approach[J]. Prenat Diagn,2015,35(7):656-662.
[3] MELLIS R,CHANDLER N,JENKINS L,et al.The role of sonographic phenotyping in delivering an efficient noninvasive prenatal diagnosis service for FGFR3-related skeletal dysplasias[J]. Prenat Diagn,2020,40(7):785-791.
[4] MONNI G,IUCULANO A.Re:ISUOG Practice Guidelines:invasive procedures for prenatal diagnosis[J]. Ultrasound Obstet & Gyne,2017,49(3):414-415.
[5] PERGAMENT E,CUCKLE H,ZIMMERMANN B,et al.Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort[J]. Obstet Gynecol,2014,124(2 Pt 1):210-218.
[6] SENTILHES L,SALOMON L J,VAYSSIÈRE C. Cell-free DNA analysis for noninvasive examination of trisomy[J]. N Engl J Med,2015,373(26):2581-2582.
[7] NORTON M E,WAPNER R J.Cell-free DNA analysis for noninvasive examination of trisomy[J]. N Engl J Med,2015,373(26):2582.
[8] LO Y M,CORBETTA N,CHAMBERLAIN P F,et al.Presence of fetal DNA in maternal plasma and serum[J]. Lancet,1997,350(9076):485-487.
[9] TAGLAUER E S,WILKINS-HAUG L,BIANCHI D W.Review:cell-free fetal DNA in the maternal circulation as an indication of placental health and disease[J].Placenta,2014,35(Suppl):S64-S68.
[10] ALBERRY M,MADDOCKS D,JONES M,et al.Free fetal DNA in maternal plasma in anembryonic pregnancies:confirmation that the origin is the trophoblast[J]. Prenat Diagn,2007,27(5):415-418.
[11] FAAS B H,DE LIGT J,JANSSEN I,et al.Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells[J]. Expert Opin Biol Ther,2012,12(Suppl 1):S19-S26.
[12] GUPTA A K,HOLZGREVE W,HUPPERTZ B,et al.Detection of fetal DNA and RNA in placenta-derived syncytiotrophoblast microparticles generated in vitro[J]. Clin Chem,2004,50(11):2187-2190.
[13] LUI Y Y,CHIK K W,CHIU R W,et al.Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation[J]. Clin Chem,2002,48(3):421-427.
[14] HAGHIAC M,VORA N L,BASU S,et al.Increased death of adipose cells,a path to release cell-free DNA into systemic circulation of obese women[J]. Obesity,2012,20(11):2213-2219.
[15] DRURY S,HILL M,CHITTY L S.Cell-free fetal DNA testing for prenatal diagnosis[J]. Adv Clin Chem,2016,76:1-35.
[16] LO Y M,TEIN M S,LAU T K,et al.Quantitative analysis of fetal DNA in maternal plasma and serum:implications for noninvasive prenatal diagnosis[J]. Am J Hum Genet,1998,62(4):768-775.
[17] LO Y M,HJELM N M,FIDLER C,et al.Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma[J]. N Engl J Med,1998,339(24):1734-1738.
[18] HU H,LIU H,PENG C,et al.Clinical experience of non-invasive prenatal chromosomal aneuploidy testing in 190,277 patient samples[J]. Curr Mol Med,2016,16(8):759-766.
[19] BARRETT A N,XIONG L,TAN T Z,et al.Measurement of fetal fraction in cell-free DNA from maternal plasma using a panel of insertion/deletion polymorphisms[J]. PLoS One,2017,12(10):e0186771.
[20] TSUI N B,JIANG P Y,CHOW K C,et al.High resolution size analysis of fetal DNA in the urine of pregnant women by paired-end massively parallel sequencing[J]. PLoS One,2012,7(10):e48319.
[21] QIAO L W,YU B,LIANG Y T,et al. Sequencing shorter cfDNA fragments improves the fetal DNA fraction in noninvasive prenatal testing[J]. Am J Obstet Gynecol,2019,221(4):345.e1-345345.e11.
[22] BRINKMAN E K,CHEN T,DE HAAS M,et al. Kinetics and fidelity of the repair of Cas9-induced double-strand DNA breaks[J]. Mol Cell,2018,70(5):801-813.e6.
[23] KHIER S,LOHAN L. Kinetics of circulating cell-free DNA for biomedical applications:critical appraisal of the literature[J]. Future Sci OA,2018,4(4):FSO295.
[24] HARTWIG T S,AMBYE L,SØRENSEN S,et al. Discordant non-invasive prenatal testing (NIPT)-a systematic review[J]. Prenat Diagn,2017,37(6):527-539.
[25] WRIGHT D,WRIGHT A,NICOLAIDES K H.A unified approach to risk assessment for fetal aneuploidies[J]. Ultrasound Obstet & Gyne,2015,45(1):48-54.
[26] XUE X Y,TEARE M D,HOLEN I,et al.Optimizing the yield and utility of circulating cell-free DNA from plasma and serum[J]. Clin Chim Acta,2009,404(2):100-104.
[27] HUNG E C W,CHIU R W K,LO Y M D. Detection of circulating fetal nucleic acids:a review of methods and applications[J]. J Clin Pathol,2009,62(4):308-313.
[28] YOKOTA M,TATSUMI N,NATHALANG O,et al.Effects of heparin on polymerase chain reaction for blood white cells[J]. J Clin Lab Anal,1999,13(3):133-140.
[29] NORTON S E,LUNA K K,LECHNER J M,et al.A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device[J]. J Clin Lab Anal,2013,27(4):305-311.
[30] NORTON S E,LECHNER J M,WILLIAMS T,et al.A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR[J]. Clin Biochem,2013,46(15):1561-1565.
[31] TRIGG R M,MARTINSON L J,PARPART-LI S,et al.Factors that influence quality and yield of circulating-free DNA:a systematic review of the methodology literature[J]. Heliyon,2018,4(7):e00699.
[32] PARPART-LI S,BARTLETT B,POPOLI M,et al.The effect of preservative and temperature on the analysis of circulating tumor DNA[J]. Clin Cancer Res,2017,23(10):2471-2477.
[33] WONG F C,SUN K,JIANG P Y,et al.Cell-free DNA in maternal plasma and serum:a comparison of quantity,quality and tissue origin using genomic and epigenomic approaches[J]. Clin Biochem,2016,49(18):1379-1386.
[34] VALLÉE A,MARCQ M,BIZIEUX A,et al. Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients[J]. Lung Cancer,2013,82(2):373-374.
[35] REPISKÁ G,KONEČNÁ B,SHELKE G V,et al. Is the DNA of placental origin packaged in exosomes isolated from plasma and serum of pregnant women?[J]. Clin Chem Lab Med,2018,56(6):e150-e153.
[36] PAGE K,HAVA N,WARD B,et al.Detection of HER2 amplification in circulating free DNA in patients with breast cancer[J]. Br J Cancer,2011,104(8):1342-1348.
[37] SHERWOOD J L,CORCORAN C,BROWN H,et al.Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC)[J]. PLoS One,2016,11(2):e0150197.
[38] KINNINGS S L,GEIS J A,ALMASRI E,et al.Factors affecting levels of circulating cell-free fetal DNA in maternal plasma and their implications for noninvasive prenatal testing[J]. Prenat Diagn,2015,35(8):816-822.
[39] ASHOOR G,SYNGELAKI A,POON L C Y,et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation:relation to maternal and fetal characteristics[J]. Ultrasound Obstet & Gyne,2013,41(1):26-32.
[40] WANG E,BATEY A,STRUBLE C,et al.Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma[J]. Prenat Diagn,2013,33(7):662-666.
[41] ZHOU Y,ZHU Z Y,GAO Y,et al.Effects of maternal and fetal characteristics on cell-free fetal DNA fraction in maternal plasma[J]. Reprod Sci,2015,22(11):1429-1435.
[42] CANICK J A,PALOMAKI G E,KLOZA E M,et al.The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies[J]. Prenat Diagn,2013,33(7):667-674.
[43] HEDRIANA H,MARTIN K,SALTZMAN D,et al.Cell-free DNA fetal fraction in twin gestations in single-nucleotide polymorphism-based noninvasive prenatal screening[J]. Prenat Diagn,2020,40(2):179-184.
[44] HUI L,BETHUNE M,WEEKS A,et al.Repeated failed non-invasive prenatal testing owing to low cell-free fetal DNA fraction and increased variance in a woman with severe autoimmune disease[J]. Ultrasound Obstet Gynecol,2014,44(2):242-243.
[45] HUI C Y,TAN W C,TAN E L,et al.Repeated failed non-invasive prenatal testing in a woman with immune thrombocytopenia and antiphospholipid syndrome:lessons learnt[J]. BMJ Case Rep,2016,2016:bcr2016216593.
[46] BURNS W,KOELPER N,BARBERIO A,et al.The association between anticoagulation therapy,maternal characteristics,and a failed cfDNA test due to a low fetal fraction[J]. Prenat Diagn,2017,37(11):1125-1129.
[47] MA G C,WU W J,LEE M H,et al.Low-molecular-weight heparin associated with reduced fetal fraction and subsequent false-negative cell-free DNA test result for trisomy 21[J]. Ultrasound Obstet Gynecol,2018,51(2):276-277.
[48] CANICK J A,KLOZA E M,LAMBERT-MESSERLIAN G M,et al. DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations[J]. Prenat Diagn,2012,32(8):730-734.
[49] HAHN S,RUSTERHOLZ C,HÖSLI I,et al. Cell-free nucleic acids as potential markers for preeclampsia[J]. Placenta,2011,32(Suppl):S17-S20.
[50] KNIGHT M,REDMAN C W,LINTON E A,et al.Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclamptic pregnancies[J]. Br J Obstet Gynaecol,1998,105(6):632-640.
[51] RAVA R P,SRINIVASAN A,SEHNERT A J,et al.Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X[J]. Clin Chem,2014,60(1):243-250.
[52] JORGEZ C J,BISCHOFF F Z.Improving enrichment of circulating fetal DNA for genetic testing:size fractionation followed by whole gene amplification[J]. Fetal Diagn Ther,2009,25(3):314-319.
[53] LI Y,ZIMMERMANN B,RUSTERHOLZ C,et al.Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms[J]. Clin Chem,2004,50(6):1002-1011.
[54] HELLWIG S,NIX D A,GLIGORICH K M,et al.Automated size selection for short cell-free DNA fragments enriches for circulating tumor DNA and improves error correction during next generation sequencing[J]. PLoS One,2018,13(7):e0197333.
[55] HAHN T,DRESE K S,O'SULLIVAN C K. Microsystem for isolation of fetal DNA from maternal plasma by preparative size separation[J]. Clin Chem,2009,55(12):2144-2152.
[56] YANG Q W,DU Z W,SONG Y,et al.Size-selective separation and overall-amplification of cell-free fetal DNA fragments using PCR-based enrichment[J]. Sci Rep,2017,7:40936.
[57] LIU L L,GUO Z L,HUANG Z Z,et al.Size-selective separation of DNA fragments by using lysine-functionalized silica particles[J]. Sci Rep,2016,6:22029.
[58] HU P,LIANG D,CHEN Y Y,et al.An enrichment method to increase cell-free fetal DNA fraction and significantly reduce false negatives and test failures for non-invasive prenatal screening:a feasibility study[J]. J Transl Med,2019,17(1):124.
[59] ZENG W,ZHU J J,QI H,et al.Comparison of two superparamagnetic purification magnetic beads-based screening and enrichment techniques for isolating cell-free fetal DNA from maternal plasma for non-invasive prenatal screening[J]. Chin J Med Genet,2024,41(7):797-802.
[60] SCHIMANSKI B,KRÄUCHI R,STETTLER J,et al.Fetal RHD screening in RH1 negative pregnant women:experience in Switzerland[J]. Biomedicines,2023,11(10):2646.
[61] PARDI C,HELLBERG Å,ISAKSON P.Single-exon fetal RHD genotyping:a 31-month follow up in the obstetric population of Western Sweden[J]. Trasfusione Del Sangue,2024.
[62] SONG W Q,ZHOU S H,SHAO L N,et al.Non-invasive fetal ABO genotyping in maternal plasma using real-time PCR[J]. Clin Chem Lab Med,2015,53(12):1943-1950.
[63] RIENECK K,EGEBERG HOTHER C,CLAUSEN F,et al.Next generation sequencing-based fetal ABO blood group prediction by analysis of cell-free DNA from maternal plasma[J]. Transfus Med Hemother,2020,47(1):45-53.
[64] O’BRIEN H,HYLAND C,SCHOEMAN E,et al. Non-invasive prenatal testing (NIPT) for fetal Kell,Duffy and Rh blood group antigen prediction in alloimmunised pregnant women:power of droplet digital PCR[J]. Br J Haematol,2020,189(3):e90-e94.
[65] CROWTHER C,MIDDLETON P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation[J]. Cochrane Database Syst Rev,2000,1997(2):CD000021.
[66] CLAUSEN F B,DAMKJÆR M B,DZIEGIEL M H. Noninvasive fetal RhD genotyping[J]. Transfus Apher Sci,2014,50(2):154-162.
[67] CLAUSEN F B.Lessons learned from the implementation of non-invasive fetal RHD screening[J]. Expert Rev Mol Diagn,2018,18(5):423-431.
[68] BILLS V L,SOOTHILL P W.Fetal blood grouping using cell free DNA-An improved service for RhD negative pregnant women[J]. Transfus Apher Sci,2014,50(2):148-153.
[69] KENT J,FARRELL A M,SOOTHILL P.Routine administration of Anti-D:the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice[J]. BMC Pregnancy Childbirth,2014,14:87.
[70] DANIELS G,VAN DER SCHOOT C E,OLSSON M L. Report of the fourth International Workshop on molecular blood group genotyping[J]. Vox Sang,2011,101(4):327-332.
[71] DE HAAS M,THURIK F F,VAN DER PLOEG C P,et al. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis:prospective cohort study of a nationwide programme in the Netherlands[J]. BMJ,2016,355:i5789.
[72] CLAUSEN F B,CHRISTIANSEN M,STEFFENSEN R,et al.Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis[J]. Transfusion,2012,52(4):752-758.
[73] HAIMILA K,SULIN,KUOSMANEN M,et al.Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland[J]. Acta Obstet Gynecol Scand,2017,96(10):1228-1233.
[74] CHITTY L S,FINNING K,WADE A,et al.Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation:population based cohort study[J]. BMJ,2014,349:g5243.
[75] LE PICHON J B,RIORDAN S M,WATCHKO J,et al. The neurological sequelae of neonatal hyperbilirubinemia:definitions,diagnosis and treatment of the kernicterus spectrum disorders (KSDs)[J]. Curr Pediatr Rev,2017,13(3):199-209.
[76] DELANEY M,MATTHEWS D C.Hemolytic disease of the fetus and newborn:managing the mother,fetus,and newborn[J]. Hematology Am Soc Hematol Educ Program,2015,2015:146-151.
[77] ZIPRIN J H,PAYNE E,HAMIDI L,et al.ABO incompatibility due to immunoglobulin G anti-B antibodies presenting with severe fetal anaemia[J]. Transfus Med,2005,15(1):57-60.
[78] DZIEGIEL M H,KROG G R,HANSEN A T,et al.Laboratory monitoring of mother,fetus,and newborn in hemolytic disease of fetus and newborn[J]. Transfus Med Hemother,2021,48(5):306-315.
[79] DONNEBORG M L,HANSEN B M,VANDBORG P K,et al.Extreme neonatal hyperbilirubinemia and kernicterus spectrum disorder in Denmark during the years 2000—2015[J]. J Perinatol,2020,40(2):194-202.
[80] MARI G,DETER R L,CARPENTER R L,et al.Noninvasive diagnosis by Doppler ultrasonography of fetal Anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses[J]. N Engl J Med,2000,342(1):9-14.
[81] ZIMMERMAN R,CARPENTER R J Jr,DURIG P,et al. Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation:a prospective multicentre trial with intention-to-treat[J]. BJOG,2002,109(7):746-752.
[82] RIENECK K.Cell-free DNA and next-generation sequencing for prenatal diagnosis[J]. Methods Mol Biol,2024,2753:583-609.

无创胎儿游离DNA血型检测在产前诊断中的研究进展^*

Advances in Non-invasive Cell-free Fetal DNA Blood Group Testing in Prenatal Diagnosis

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	庄远, 于洋. 输血（医学）科基于离心分离技术建立单采/血液净化治疗体系的探索[J]. 临床输血与检验, 2024, 26(6): 721-725.
[2]	刘晓敏, 庄远, 于洋. 我国医疗机构输血科开展输血治疗的现状调查报告[J]. 临床输血与检验, 2024, 26(6): 740-743.
[3]	沈倩云, 程文国, 侯书宁, 姚根宏. ABO新生儿溶血病患儿血浆中血管细胞粘附分子-1的表达差异与意义^*[J]. 临床输血与检验, 2024, 26(6): 744-749.
[4]	王丹婷, 龙红惠, 牛迎迎, 黄春妍. 微柱凝胶法交叉配血次侧不合的原因探讨及临床意义分析[J]. 临床输血与检验, 2024, 26(6): 750-754.
[5]	车扬, 刘铮, 周小玉. 原发性肝癌肝切除患者术后不同种类血浆输注疗效的回顾性分析[J]. 临床输血与检验, 2024, 26(6): 755-761.
[6]	郑妍, 王文婷, 杨龙飞, 王琼, 穆士杰. 8例RhD变异型的血清学特征及基因序列分析[J]. 临床输血与检验, 2024, 26(6): 762-765.
[7]	梁春艳, 段莉, 刘友迎, 刘方久. 住院患者输血相关循环超负荷的危险因素及预测模型的构建与验证[J]. 临床输血与检验, 2024, 26(6): 771-776.
[8]	蔡茵, 陈至颖, 蒋苓, 任亚娜, 郑岚, 周国平. 上海地区无偿献血人群HLA抗体筛查分析[J]. 临床输血与检验, 2024, 26(6): 777-780.
[9]	郭瑞, 侯云, 苏常山, 钟建玲, 甄志军, 何燕琴, 鲍琳, 崔立晔, 孙俊艳, 张剑, 李浩, 王振兴, 张微, 李晶, 付恒, 蔡晓波, 卢然然, 沈有华, 王登峰, 胡官林, 刘洋, 邱艳. 采用发病率-窗口期模型分析2018—2022年国内21家采供血机构输血传播HBV检测残余风险^*[J]. 临床输血与检验, 2024, 26(6): 781-786.
[10]	李艳, 周丽玲, 马肇泽, 祝凯捷, 王辰龙. 25例B亚型/AB亚型的ABO基因序列分析^*[J]. 临床输血与检验, 2024, 26(6): 787-791.
[11]	李欣, 杨俊鸿. 我国妊娠期妇女血小板抗体阳性率Meta分析^*[J]. 临床输血与检验, 2024, 26(6): 805-811.
[12]	明静, 丁凯阳, 胡茂贵, 王馨辰. 阿伐曲泊帕联合rhTPO在恶性血液病自体造血干细胞移植中的临床疗效分析^*[J]. 临床输血与检验, 2024, 26(6): 812-817.
[13]	王嘉琪, 肖军, 李翠莹. mTOR通路在调控造血干细胞自我更新和分化中的研究进展^*[J]. 临床输血与检验, 2024, 26(6): 818-824.
[14]	王淑君, 李兆杰, 杨奕, 栾建凤. 血小板衍生制品促进创面愈合的研究进展^*[J]. 临床输血与检验, 2024, 26(6): 825-834.
[15]	杨俊鸿, 代华友, 杨冬燕, 黄霞. 献血不良反应严重程度分级标准及其应用进展^*[J]. 临床输血与检验, 2024, 26(6): 843-848.